|
Delayed
Nasdaq
21:00:00 23/12/2024 GMT
|
5-day change | 1st Jan Change | ||
| 0.2531 USD | +4.20% |
|
-.--% | - |
| 09-18 | Neuphoria Therapeutics Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 07-23 | Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. for $35 million. | CI |
Evolution of the Average Target: BIONOMICSSADR
Data source:
Neuphoria Therapeutics Inc.(NEUP)
Evolution of the Target Price: BIONOMICSSADR
Data source:
Neuphoria Therapeutics Inc.(NEUP)
Changes in Analyst Recommendations: BIONOMICSSADR
Data source:
Neuphoria Therapeutics Inc.(NEUP)
73202e7b0352c76bb34630.Fa4RBU01Jo2b-9-fi1D0Knag7N42dxrr-Wh7KWPKs4A.J8x2Th9ZSbnfyLrc4TyXZAPJupRvD1KBiCIsQCi_47gmzVxgGXN-58SovA~fdaf35437eae1cea6f71841a6b904ee7
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +11.79% | |||||
| +23.73% | |||||
| +22.76% | |||||
| +10.75% | |||||
| +25.05% | |||||
| +20.83% | |||||
| +45.83% | |||||
| +3.91% | |||||
| +82.1% | |||||
| Average | +27.42% | |||||
| Weighted average by Cap. | +23.56% |
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.510
Average target price
-
Analyst Consensus Detail
Consensus revision (last 18 months)
- Stock Market
- Stocks
- NEUP Stock
- BNOX Stock
- Consensus BIONOMICSSADR
Select your edition
All financial news and data tailored to specific country editions
